- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Brimonidine Tartrate Ophthalmic Solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 2 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 90
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Allergic Conjunctivitis
- Interventions
- Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee + 1 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Drug
- Lead sponsor
- Padagis LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Ocular Hypertension
- Interventions
- brimonidine/timolol fixed combination
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Seasonal Allergic Conjunctivitis
- Interventions
- Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more
- Conditions
- Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
- Interventions
- Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more
- Conditions
- Glaucoma
- Interventions
- Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost
- Drug
- Lead sponsor
- Innovative Medical
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Intraocular Pressure
- Interventions
- Alphagan, Phenylephrine, Tropicamide
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hyperemia
- Interventions
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 1 more
- Conditions
- Ocular Hypertension
- Interventions
- brimonidine/timolol fixed combination
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999
- U.S. locations
- 1
- States / cities
- Artesia, California
- Conditions
- Glaucoma, Open Angle
- Interventions
- brimonidine, timolol
- Drug
- Lead sponsor
- Chicago Center for Vision Research
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more
- Conditions
- Dermatochalasis of Eyelid, Ptosis, Eyelid, Ectropion, Entropion
- Interventions
- Brimonidine Topical
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Ocular Redness
- Interventions
- BTOS-HA, Lumify®
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 11
- States / cities
- Glendale, California • Newport Beach, California • Northbrook, Illinois + 8 more
- Conditions
- Presbyopia
- Interventions
- BRIMOCHOL™ PF, Carbachol PF, Brimonidine tartrate
- Drug
- Lead sponsor
- Visus Therapeutics
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 15
- States / cities
- Glendale, California • Rancho Cordova, California • Jacksonville, Florida + 10 more
- Conditions
- Presbyopia
- Interventions
- BRIMOCHOL™ PF, Carbachol PF, Vehicle
- Drug
- Lead sponsor
- Visus Therapeutics
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 629 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 39 more
- Conditions
- Erythema, Rosacea
- Interventions
- CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 4
- States / cities
- Evansville, Indiana • Louisville, Kentucky • Austin, Texas + 1 more
- Conditions
- Rosacea
- Interventions
- Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251), Azelaic Acid Cream, Metronidazole gel, Metronidazole cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glaucoma
- Interventions
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, timolol maleate 0.5%, latanoprost 0.005%
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Brimonidine purite 0.15%, Dorzolamide 2%, Brinzolamide 1%
- Drug
- Lead sponsor
- Northwestern Ophthalmic Institute S.C.
- Other
- Eligibility
- 41 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Glenview, Illinois
- Conditions
- Glaucoma, Open-Angle
- Interventions
- 400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant)
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Artesia, California
- Conditions
- Presbyopia, Refractive Errors, Eye Diseases
- Interventions
- Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle proprietary ophthalmic solution
- Drug
- Lead sponsor
- LENZ Therapeutics, Inc
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 5
- States / cities
- Chandler, Arizona • Glendale, California • Andover, Massachusetts + 2 more
- Conditions
- Ocular Hypertension
- Interventions
- brimonidine/timolol fixed combination
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky